Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients
Status:
Completed
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The GrantPax study is a multicenter phase 4 geriatric assessment directed trial to evaluate
gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients. The primary objective
is that CGA-stratified patients do not decline in their CGA performance in response to
chemotherapy measured as a loss of five points or less in the Barthel's ADL, (ADL1 vs. ADL2
during core CGA assessment).